Non-Inhibitor Data Secure Roche's Competitive Position In Hemophilia A

Roche's Genentech reported positive top-line Phase III results for Hemlibra in a second hemophilia A population – patients without inhibitors – just four days after its approval for patients with inhibitors, which will broaden the product's market and may improve its competitive position.

Roche's Genentech Inc. reported positive top-line results for Hemlibra (emicizumab-kxwh) in the treatment of hemophilia A patients who do not have inhibitors of factor VIII and the data appear to boost the newly approved product's competitive position against the high-cost standard of care.

Detailed data from the Phase III HAVEN 3 clinical trial, which will be presented at a future medical meeting, may...